Pharmacyclics (PCYC +1.4%) moves up after Roth Capital ups its price target on the shares to $42...


Pharmacyclics (PCYC +1.4%) moves up after Roth Capital ups its price target on the shares to $42 from $21. Roth thinks the market potential for the drug developer's lymphoma treatment ibrutinib is quite large, and it's impressed by the speed of the clinical program for the drug.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs